SP Scientific details expanded capabilities in pharmaceutical processing
Company now able to offer a one-source solution for a complete range of pharmaceutical processing equipment.
From lyophilizers/freeze dryers, vial washers and sterilization tunnels right through to automated systems for filling, loading/unloading, capping and external washing of vials, PennTech, Hull and VirTis brands uniquely position SP Scientific as the only company in the US with capability to manufacture complete aseptic vial processing lines.
As a market leader in R&D, pilot and production scale freeze dryers, SP Scientific is well versed in helping pharmaceutical companies increase the shelf-life of their products. With the growing trend in the pharmaceutical industries to remove human handling from aseptic applications, the recent acquisition of Penntech perfectly complements SP Scientific’s vision to offer pharmaceutical manufacturers end-to-end automated solutions for continuous aseptic processing.
SP Scientific’s Paul Coiteux, Director of Production Lyophilizer Technical Sales and Kain Johnson, Business Development, recently sat down for an interview to discuss SP’s new equipment capabilities, as well as how technology developments such as ControLyo nucleation technology have enabled their customers around the world to attain a level of lyophilized product homogeneity never before achieved. A video of the interview is available on the APR and SP Scientific web sites.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.